Stocks · News reference
Medicare Lab Fee Changes Impact BillionToOne, CareDx Differently
CMS aligns 2027 clinical lab fees with private payors to save $1 billion, yielding positive updates for CareDx and BillionToOne tests.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
BillionToOne's Co-Founder Sells 10,000 Shares for $1 Million
David Tsao, co-founder and CTO of BillionToOne, sold 10,000 shares for $1 million on August 25, 2026, through a pre-planned Rule 10b5-1 trading arrangement. The sale occurred after the stock declined from a 52-week high of $150.44, but Tsao retains 580,000 stock options, maintaining significant equity alignment with the company. Despite the recent share price drop following Q2 earnings, BillionToOne reported strong 64% year-over-year revenue growth.
Jim Cramer: 'You Could Make Some Money With This 5.6% Yield'
Jim Cramer likes Babcock & Wilcox and Smithfield Foods. He also advises taking some profits on BillionToOne, and calls Eton Pharma a winner.
CareDx shares are trading higher after BTIG maintained its Buy rating on the stock and raised its price target from $60 to $74.
BTIG Maintains Buy on CareDx, Raises Price Target to $74
BTIG analyst Mark Massaro maintains CareDx (NASDAQ:CDNA) with a Buy and raises the price target from $60 to $74.
8-K/A filing — CareDx, Inc. (CDNA)
Filed: 2026-09-16 AccNo: 0001217234-26-000052 Size: 10 MB Item 2.01: Completion of Acquisition or Disposition of Assets Item 9.01: Financial Statements and Exhibits